A detailed history of Bank Of America Corp transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 207,969 shares of RLMD stock, worth $725,811. This represents 0.0% of its overall portfolio holdings.

Number of Shares
207,969
Previous 210,576 1.24%
Holding current value
$725,811
Previous $979,000 36.36%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$2.93 - $4.94 $7,638 - $12,878
-2,607 Reduced 1.24%
207,969 $623,000
Q1 2024

May 15, 2024

SELL
$3.1 - $6.8 $170 - $374
-55 Reduced 0.03%
210,576 $979,000
Q4 2023

Feb 14, 2024

SELL
$2.45 - $4.22 $64,361 - $110,859
-26,270 Reduced 11.09%
210,631 $872,000
Q2 2023

Aug 14, 2023

BUY
$2.22 - $3.54 $443,038 - $706,467
199,567 Added 534.54%
236,901 $582,000
Q1 2023

May 12, 2023

BUY
$2.24 - $4.76 $46,533 - $98,884
20,774 Added 125.45%
37,334 $84,000
Q4 2022

Feb 10, 2023

BUY
$2.17 - $35.84 $5,848 - $96,588
2,695 Added 19.44%
16,560 $57,000
Q3 2022

Nov 14, 2022

BUY
$18.3 - $37.02 $92,927 - $187,987
5,078 Added 57.79%
13,865 $513,000
Q2 2022

Aug 12, 2022

BUY
$16.5 - $30.34 $33,841 - $62,227
2,051 Added 30.45%
8,787 $166,000
Q1 2022

May 16, 2022

SELL
$16.72 - $26.99 $61,362 - $99,053
-3,670 Reduced 35.27%
6,736 $182,000
Q4 2021

Feb 08, 2022

SELL
$16.93 - $26.82 $31,743 - $50,287
-1,875 Reduced 15.27%
10,406 $235,000
Q3 2021

Nov 15, 2021

BUY
$21.86 - $34.77 $132,996 - $211,540
6,084 Added 98.18%
12,281 $322,000
Q2 2021

Sep 13, 2021

BUY
$29.55 - $39.15 $183,121 - $242,612
6,197 New
6,197 $199,000

Others Institutions Holding RLMD

About RELMADA THERAPEUTICS, INC.


  • Ticker RLMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,608,500
  • Market Cap $99.8M
  • Description
  • Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...
More about RLMD
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.